The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.

Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...

The National Cancer Institute (“NCI”), under its Cooperative Research and Development Agreement (“CRADA”) with PDS Biotech, will lead the Phase 1/2 clinical trial evaluating the combination of ...

Antibody-drug conjugates (ADCs ... showing potential in treating HER2-expressing cancers. M1231, which targets MUC1 and EGFR, ...

“MUC1 is over-expressed in multiple solid tumors ... and in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint ...

“MUC1 is over-expressed in multiple solid tumors including colon, pancreatic, ovarian, breast, and NSCLC, and is associated with drug resistance and poor patient outcomes. This results in an ...

"MUC1 is over-expressed in multiple solid tumors including colon, pancreatic, ovarian, breast, and NSCLC, and is associated with drug resistance and poor patient outcomes. This results in an unmet ...

(RTTNews) - PDS Biotech (PDSB), a late-stage immunotherapy company focused on cancer treatments, announced Thursday that the U.S. Food and Drug Administration or FDA has cleared its ...